Selecta Biosciences has dosed the first patient in a Phase I clinical trial evaluating the safety and tolerability of SEL-403 in combination with LMB-100 for the treatment of mesothelioma.

The trial seeks to enrol up to 18 patients with malignant pleural or peritoneal mesothelioma who have undergone at least one regimen of chemotherapy.

It is being carried out under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health in the US.

“Mesothelioma remains one of the deadliest and most challenging-to-treat forms of cancer.”

In the trial, patients will receive up to four treatment cycles, each featuring an initial dose of SVP-Rapamycin in combination with LMB-100 on day one followed by two doses of LMB-100 alone on days three and five.

The trial expects to provide data on pharmacokinetics, anti-drug antibody (ADA) levels, as well as an objective response rate assessment.

The trial’s senior investigator Raffit Hassan said: “Mesothelioma remains one of the deadliest and most challenging-to-treat forms of cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Recombinant immunotoxins hold the potential to induce marked anti-tumour activity if anti-drug antibodies are prevented and sufficient cycles of therapy can be administered.”

Selecta is currently developing SEL-403 that features SVP-Rapamycin, the company’s proprietary, clinical-stage anti-drug antibody (ADA) prevention and immune tolerance technology.

LMB-100 is a recombinant immunotoxin that targets mesothelin, a protein expressed in almost all mesotheliomas and pancreatic adenocarcinomas, and a high percentage of other malignancies, such as lung, breast and ovarian cancers.